FRANKFURT/NEW YORK (dpa-AFX Broker) - A weaker business outlook from Repligen than expected by experts also dragged down the shares of Sartorius on Wednesday. The shares of the German pharmaceutical and laboratory supplier fell by 3.4 percent to 323.40 euros in the early afternoon. The shares of the US supplier of materials for the production of biological drugs fell by around nine percent in pre-morning US trading.

Meanwhile, Sartorius had already presented its targets for 2024 at the end of January. After a weak year, the DAX-listed company wants to grow again and increase profitability. The shares then continued their recovery. Since then, apart from brief outliers, the share price has fluctuated between around 320 and 340 euros./mis/jha/